Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Baxter
US Army
Argus Health
Farmers Insurance
Mallinckrodt
Queensland Health
Fish and Richardson
Dow
Cerilliant

Generated: October 20, 2017

DrugPatentWatch Database Preview

NASACORT Drug Profile

« Back to Dashboard

What is the patent landscape for Nasacort, and when can generic versions of Nasacort launch?

Nasacort is a drug marketed by Sanofi Aventis Us and is included in three NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in NASACORT is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Eighty-five suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

Summary for Tradename: NASACORT

US Patents:0
Applicants:1
NDAs:3
Bulk Api Vendors: see list61
Clinical Trials: see list5
Patent Applications: see list5,172
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NASACORT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
NASACORT
triamcinolone acetonide
AEROSOL, METERED;NASAL019798-001Jul 11, 1991DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
NASACORT ALLERGY 24 HOUR
triamcinolone acetonide
SPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
NASACORT ALLERGY 24 HOUR
triamcinolone acetonide
SPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
NASACORT ALLERGY 24 HOUR
triamcinolone acetonide
SPRAY, METERED;NASAL020468-002Oct 11, 2013OTCYesYes► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
NASACORT HFA
triamcinolone acetonide
SPRAY, METERED;NASAL020784-001Apr 7, 2004DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NASACORT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
NASACORT
triamcinolone acetonide
AEROSOL, METERED;NASAL019798-001Jul 11, 1991► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NASACORT

Drugname Dosage Strength RLD Submissiondate
triamcinolone acetonideNasal Spray0.055 mg/SprayNasacort AQ12/29/2005
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Accenture
UBS
Chinese Patent Office
Chubb
Cerilliant
Fish and Richardson
Healthtrust
Merck
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot